Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RO4598715, KOS-862
Epothilone D · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase I - Epothilone D Dose Escalation | EXPERIMENTAL | - |
| Phase II - Epothilone D Maximum Tolerated Dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Epothilone D | DRUG | ≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks |
| Herceptin | DRUG | 4mg/kg iv loading dose, followed by 2mg/kg iv weekly |
Inclusion Criteria: * women \>=18 years; * locally advanced or metastatic breast cancer; * HER-2 overexpression (FISH + or IHC 3+); * \>=1 measurable lesion; * up to one prior anthracycline-based chemotherapy regimen in a metastatic setting. Exclusion Criteria: * pre-existing neuropathy \>=grade ...
Top 20 of 87 competitors
Epothilone D is an investigational small molecule being studied for the treatment of breast cancer. It has been evaluated specifically in patients with HER-2 positive advanced or metastatic breast cancer, in combination with trastuzumab (Herceptin). It is not an approved therapy and remains in clinical development.
Epothilone D targets tubulin proteins, including TUBB4B, TUBB1, TUBA3C, TUBA4A, TUBB3, and TUBA1A. It acts as a tubulin stabiliser, binding to these targets to promote microtubule stabilization. This mechanism interferes with microtubule dynamics, which is relevant to its evaluation in breast cancer.
Epothilone D is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating this agent in breast cancer.
Epothilone D is in Phase 1 clinical development. It has not been approved by the FDA or any regulatory agency and is considered investigational. The Phase 1 program has completed one trial, with no active trials currently reported.
Epothilone D has been studied in one completed Phase 1 trial, NCT00337649, titled "A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer." The trial enrolled 27 female patients aged 18 years and older in Spain.